Regulation of collagenolytic cysteine protease synthesis by estrogen in osteoclasts

Steroids

Volumn 65, Issue 7, 2000, Pages 371-378

  Furuyama, Naoki ^a   Fujisawa, Yukio ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Bone resorption; Cathepsin B; Cathepsin K; Cathepsin L; Estradiol 17 ; Steroid

Indexed keywords

CATHEPSIN B; CATHEPSIN K; CATHEPSIN L; CYSTEINE PROTEINASE; ESTRADIOL; HYDROXYPROLINE;

ANIMAL CELL; ARTICLE; BONE TURNOVER; CALVARIA; CELL DIFFERENTIATION; COLLAGEN DEGRADATION; ENZYME SYNTHESIS; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BONE AND BONES; CATHEPSIN B; CATHEPSINS; CELLS, CULTURED; CYSTEINE ENDOPEPTIDASES; DNA PRIMERS; ENDOPEPTIDASES; ESTRADIOL; FEMALE; HYDROXYPROLINE; MALE; MICE; MICE, INBRED ICR; ORGAN CULTURE TECHNIQUES; OSTEOCLASTS; OVARIECTOMY; OVARY; RNA, MESSENGER;

EID: 0033920164     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(00)00097-0     Document Type: Article

References (28)

1. Prestwood K.M., Pilbeam C.C., Raisz L.G. Treatment of osteoporosis. Annu Rev Med. 46:1995;249-256.
2. Prince R.L., Smith M., Dick I.M., et al. Prevention of postmenopausal osteoporosis a comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med. 325:1991;1189-1195.
3. Kremer M., Judd J., Rifkin B., Auszmann J., Oursler M.J. Estrogen modulation of osteoclast lysosomal enzyme secretion. J Cell Biochem. 57:1995;271-279.
4. Tezuka K., Tezuka Y., Maejima A., et al. Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J Biol Chem. 269:1994;1106-1109.
5. Inaoka T., Bilbe G., Ishibashi O., Tezuka K., Kumegawa M., Kokubo T. Molecular cloning of human cDNA for cathepsin K novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun. 206:1995;89-96.
6. Inui T., Ishibashi O., Inaoka T., et al. Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J Biol Chem. 272:1997;8109-8112.
7. Gelb B.D., Shi G.-P., Chapman H.A., Desnick R.J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 273:1996;1236-1238.
8. Maroteaux P., Lamy M. La pycnodysostose. Presse Med. 70:1962;999-1002.
9. Andren L., Dymling J.F., Hogemen K.E., Wendeberg B. Osteopetrosis acro-osteolytica a syndrome of osteopetrosis, acro-osteolysis and open sutures of the skull. Acta Chir Scand. 124:1962;496-507.
10. Wronski T.J., Cintron M., Dann L.M. Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif Tissue Int. 43:1988;179-183.
11. Turner R.T., Wakley G.K., Hannon K.S., Bell N.H. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology. 122:1988;1146-1150.
12. Yasuda H., Shima N., Nakagawa N., et al. A novel molecular mechanism modulating osteoclast differentiation and function. Bone. 25:1999;109-113.
13. Yasuma T., Oi S., Choh N., et al. Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption. J Med Chem. 41:1998;4301-4308.
14. Barrett A.J., Kirschke H. Cathepsin B, cathepsin H, and cathepsin L. Methods Enzymol. 80:1981;535-561.
15. Woessner J.F. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys. 93:1961;440-447.
16. Akatsu T., Tamura T., Takahashi N., et al. Preparation and characterization of a mouse osteoclast-like multinucleated cell population. J Bone Miner Res. 7:1992;1297-1306.
17. Oursler M.J., Osdoby P., Pyfferoen J., Riggs B.L., Spelsberg T.C. Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci USA. 88:1991;6613-6617.
18. Oursler M.J., Pederson L., Fitzpatrick L., Riggs B.L., Spelsberg T.C. Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci USA. 91:1994;5227-5231.
19. Jilka R.L., Hangoc G., Girasole G., et al. Increased osteoclast development after estrogen loss mediation by interleukin-6 (IL-6). Science. 257:1992;88-91.
20. Girasole G., Jilka R.L., Passeri G., et al. 17β-Estradiol inhibits IL-6 production by bone marrow-derived stromal cells and osteoblasts in vitro a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest. 89:1992;883-891.
21. Poli V., Balena R., Fattori E., et al. IL-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13:1994;1189-1196.
22. Kimble R.B., Kitazawa R., Vannice J.L., Pacifici R. Persistent bone-sparing effect of IL-1 receptor antagonist a hypothesis on the role of IL-1 in ovariectomy-induced bone loss. Calcif Tissue Int. 55:1994;260-265.
23. Ammann P., Garcia I., Rizzoli R., Meyer J.M., Vassalli P., Bonjour J.P. Transgenic mice expressing high levels of soluble tumor necrosis factor (TNF) receptor-1 fusion protein are protected from bone loss caused by estrogen deficiency. J Bone Miner Res. 10:1995;S139.
24. Yamaura M., Nakamura T., Tsurukami H., et al. Local bone turnover in the metaphysis of the proximal tibia and the lumber vertebra during the early periods after ovariectomy in rats. Calcif Tissue Int. 58:1996;52-59.
25. Raisz L.G. Bone resorption in tissue culture. Factors influencing the response to parathyroid hormone. J Clin Invest. 44:1965;103-116.
26. Rodan GA. Control of bone formation and resorption: biological and clinical perspective. J Cell Biochem 1998;30/31(suppl.):55-61.
27. Pacifici R. Cytokines, estrogen, and postmenopausal osteoporosis - the second decade. Endocrinology. 139:1998;2659-2661.
28. Jilka R.L. Cytokines, bone remodeling, and estrogen deficiency a 1998 update. Bone. 23:1998;75-81.